CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
with chemotherapy and chemoradiation in locally advanced esophageal adenocarcinoma to examine the safety and efficacy of the combination of ...
Phase 2
Ann Arbor, Michigan, United States and 3 other locations
and capecitabine monotherapy in patients with metastatic pancreatic adenocarcinoma whose disease has not progressed on a first line fluoropy...
Phase 1, Phase 2
Detroit, Michigan, United States of America and 19 other locations
participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSignatur...
Phase 1, Phase 2
Detroit, Michigan, United States and 66 other locations
T-cells in Subjects with Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma...
Phase 1
Detroit, Michigan, United States and 3 other locations
first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma...
Phase 3
Ann Arbor, Michigan, United States and 203 other locations
The goal of this clinical trial is to test an experimental treatment (immunotherapy) in pancreatic cancer patients. The main research objectives are:...
Phase 1
Detroit, Michigan, United States and 14 other locations
mCRPC. Patients enrolled in the Phase 2a portion of the study will have either Small Cell Neuroendocrine Prostate Cancer(SCNC)(Cohort A) or adenocarcinoma...
Phase 1, Phase 2
Detroit, Michigan, United States and 11 other locations
after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponso...
Phase 3
Detroit, Michigan, United States and 186 other locations
and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma...
Phase 3
Ann Arbor, Michigan, United States and 165 other locations
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody ta...
Phase 1
Ann Arbor, Michigan, United States and 18 other locations
Clinical trials
Research sites
Resources
Legal